A large outbreak of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE) has been reported from the Tuscany region in Italy. Between November 2018 and May 2019, seven Tuscan hospitals notified a total of 350 cases.

This rapid risk assessment evaluates the risk of transmission and further spread of OXA-48-producing Klebsiella pneumonia e ST392 from travellers having sought medical care in Gran Canaria to healthcare facilities in their country of origin in the EU/EEA.

This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.

This outbreak of Verona integron-encoded metallo-beta-lactamase-producing carbapenem-resistant Pseudomonas aeruginosa (VIM-CRPA) surgical site infections, related to invasive procedures performed in healthcare facilities in Tijuana, Baja California, Mexico, highlights the risks associated with medical tourism for patients and healthcare systems in the countries of origin.

Communicable disease threats to public health in the European Union - Annual Epidemiological Report for 2017

Surveillance report-28 Nov 2018

This report covers the events, threats and actions taken in 2017 related to the findings of routine activities carried out by the ECDC epidemic intelligence team. The objective of epidemic intelligence at ECDC is to rapidly detect and assess public health events of any origin to ensure EU health security as defined in ECDC’s mandate.

Carbapenem resistant Enterobacteriaceae - second update

Risk assessment-27 Sep 2019

Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options.